Association of FAS gene polymorphisms with systemic lupus erythematosus: A case-control study and meta-analysis

Experimental and Therapeutic Medicine

Volumn 4, Issue 3, 2012, Pages 497-502

  Lu, Man Man ^a   Ye, Qian Ling ^a   Feng, Chen Chen ^a   Yang, Jie ^a   Zhang, Tao ^b   Li, Jing ^a   Leng, Rui Xue ^a   Pan, Hai Feng ^a   Yuan, Hui ^c   Ye, Dong Qing ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b Anhui Center for Disease Control and Prevention   (China)

^c WANNAN MEDICAL COLLEGE   (China)

Author keywords

Fas; Meta analysis; Single nucleotide polymorphisms; Systemic lupus erythematosus

Indexed keywords

FAS ANTIGEN;

ADULT; ALLELE; ARTICLE; CASE CONTROL STUDY; CHINESE; CONTROLLED STUDY; GENETIC ASSOCIATION; GENOTYPING TECHNIQUE; HAPLOTYPE; HUMAN; META ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 84863930992     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.625     Document Type: Article

References (26)

1. Akahoshi M, Nakashima H and Shirakawa T: Roles of genetic variations in signaling/immunoregulatory molecules in susceptibility to systemic lupus erythematosus. Semin Immunol 18:224-229, 2006.
2. Kaplan MJ: Apoptosis in systemic lupus erythematosus. Clin Immunol 112: 210-218, 2004.
3. Sheriff A, Gaipl US, Voll RE, Kalden JR and Herrmann M: Apoptosis and systemic lupus erythematosus. Rheum Dis Clin North Am 30: 505-527, 2004.
4. Emlen W, Niebur J and Kadera R: Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 152: 3685-3692, 1994.
5. Ren Y, Tang J, Mok MY, et al: Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus. Arthritis Rheum 48: 2888-2897, 2003.
6. Shoshan Y, Shapira I, Toubi E, et al: Accelerated Fas-mediated apoptosis of monocytes and maturing macrophages from patients with systemic lupus erythematosus: relevance to in vitro impairment of interaction with IC3b-opsonized apoptotic cells. J Immunol 167: 5963-5969, 2001.
7. Leithäuser F, Dhein J, Mechtersheimer G, et al: Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 69: 415-429, 1993.
8. Papo T, Parizot C, Ortova M, et al: Apoptosis and expression of soluble Fas mRNA in systemic lupus erythematosus. Lupus 7: 455-461, 1998.
9. Navratil JS and Ahearn JM: Apoptosis and autoimmunity: complement deficiency and systemic lupus erythematosus revisited. Curr Rheumatol Rep 2: 32-38, 2000.
10. Inazawa J, Itoh N, Abe T and Nagata S: Assignment of the human Fas antigen gene (FAS) to 10q24.1. Genomics 14: 821-822, 1992.
11. Molin S, Weiss EH, Ruzicka T and Messer G: The FAS/cd95 promoter single-nucleotide polymorphism -670 A/G and lupus erythematosus. Clin Exp Dermatol 37: 425-427, 2012.
12. Arasteh JM, Sarvestani EK, Aflaki E and Amirghofran Z: Fas gene polymorphisms in systemic lupus erythematosus and serum levels of some apoptosis-related molecules. Immunol Invest 39: 27-38, 2010.
13. Kanemitsu S, Ihara K, Saifddin A, et al: A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J Rheumatol 29: 1183-1188, 2002.
14. Lee YH, Kim YR, Ji JD, et al: Fas promoter -670 polymorphism is associated with development of anti-RNP antibodies in systemic lupus erythematosus. J Rheumatol 28: 2008-2011, 2001.
15. Huang QR, Danis V, Lassere M, Edmonds J, and Manolios N: Evaluation of a new Apo-1/Fas promoter polymorphism in rheumatoid arthritis and systemic lupus erythematosus patients. Rheumatology (Oxford) 38: 645-651, 1999.
16. Huang QR and Manolios N: Investigation of the -1377 polymorphism on the Apo-1/Fas promoter in systemic lupus erythematosus patients using allele-specific amplification. Pathology 32: 126-130, 2000.
17. Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40: 1725, 1997.
18. Shi YY and He L: SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 15: 97-98, 2005.
19. Higgins JP and Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558, 2002.
20. Mantel N and Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748, 1959.
21. DerSimonian R and Laird N: Meta-analysis in clinical trials. Control Clin Trials 7: 177-188, 1986.
22. Egger M, Davey Smith G, Schneider M, and Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634, 1997.
23. Bijl M, Horst G, Limburg PC and Kallenberg CG: Fas expression on peripheral blood lymphocytes in systemic lupus erythematosus (SLE): relation to lymphocyte activation and disease activity. Lupus 10: 866-872, 2001.
24. Huang QR, Morris D and Manolios N: Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 34: 577-582, 1997.
25. Sibley K, Rollinson S, Allan JM, et al: Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 63: 4327-4330, 2003.
26. Look DC, Pelletier MR, Tidwell RM, et al: Stat1 depends on transcriptional synergy with Sp1. J Biol Chem 270: 30264-30267, 1995.